US FDA Warns Indoco To Delve Further Into Manufacturing Deviation
Data integrity and process control found lacking
On paper, the tablet press was in control. In reality, it was not. What did that mean for the company? A lot more than it appeared to realize.
You may also be interested in...
FDA Warns Glenmark Over Temperature Excursions, Gritty Topicals
Firm should have addressed complaints of gritty topicals and compromised container/closures, and its own findings about overheated creams, the US FDA says.
Manufacturing Compliance Updates In Brief From US FDA And EU
Many of the six drug GMP warning letters the US FDA has issued since late March targeted lax testing practices, particularly at OTC firms abroad. Two EU GMP non-compliance notices highlighted data integrity shortcomings in India. FDA also posted a couple of Form 483 reports and added four facilities to its GMP import alert.
Transparency Looms Large In US FDA’s Next-Pandemic Legislative Agenda
Agency’s proposals for pandemic preparedness reauthorization would build on CARES Act provisions to gain greater visibility into global pharmaceutical supply chains, while also seeking deeper understanding of manufacturing quality management activities. Also included in FY 2024 budget request: long-sought drug destruction and drug recall authorities.